MicroRNAs (miRNAs) are some short RNAs that regulate multiple biological functions at posttranscriptional levels, such as tumorigenic processes, inflammatory lesions and cell apoptosis. Zinc finger E-box binding homeobox factor 1 (ZEB1) is a crucial mediator of epithelial-mesenchymal transition (EMT). It induces malignant progression of various cancers including human esophageal squamous-cell carcinoma (ESCC). In this study, we found that miR-128-3p was downregulated in ESCC tissues and cells by using PCR. Moreover, down-regulated expression of miR-128-3p was testified to be associated with poor prognosis of ESCC patients and might be regarded as an independent prognostic factor. Then, we examined the role of miR-128-3p in ESCC cells, and found that miR-128-3p could suppress the cell migration and invasion in vitro. Furthermore, ZEB1 was confirmed to be a direct target of miR-128-3p by luciferase reporter assay. Rescue experiments proved that EMT was regulated by miR-128-3p via suppression of ZEB1. Taken all together, we conclude that miR-128-3p suppresses EMT and metastasis via ZEB1, and miR-128-3p may be a critical mediator in ESCC.
Introduction
Esophageal cancer (EC) is one of the most serious health problems worldwide, which ranks eighth in human malignancy [1, 2] . Esophageal squamous-cell carcinoma (ESCC) is the most prevalent histological type of EC and approximately 90% occurred in Southeast Asia countries, particularly in China [3] [4] [5] . Poor clinical outcome and high mortality rate are shown in ESCC patients, due to its high-aggressive ability, distant metastasis and the resistance to adjuvant therapy [6, 7] . Therefore, it is imperative to find efficient targets for ESCC therapy.
Zinc finger E-box binding homeobox 1 (ZEB1) has a conserved homeobox region and two zinc finger domains at each end of the regions, which belongs to the ZEB family of transcription factors [8, 9] . ZEB1 can bind with target DNA sequences and repress cell adhesion molecules as well as cell polarity-associated genes to induce epithelial-mesenchymal transition (EMT) progress [10, 11] . It is expressed at low level in the normal epithelium, and is upregulated in the malignant epithelium tumors [12] [13] [14] . Aberrant expression of ZEB1 in ESCC has been reported in recent years [15] [16] [17] [18] .
MicroRNAs (miRNAs) are some short non-coding endogenous RNAs (ncRNAs) which can bind to the 3′-untranslated regions (3′-UTRs) of target mRNAs, and a large number of them can modulate biological behavior of tumors [19] [20] [21] [22] . Recently, it has been found that various miRNAs are aberrantly expressed in ESCC [23] [24] [25] [26] [27] [28] [29] [30] [31] , which indicates that these miRNAs play critical roles in carcinogenesis. In this study, we compared the expression patterns of miR-128-3p in ESCC tissues and normal tissues, and explored the function of miR-128-3p in vitro. ZEB1 was confirmed to be the direct target of miR-128-3p. These results indicate that miR-128-3p may be able to serve as a potential therapeutic target for human ESCC.
Material and Methods

Cell culture
ESCC cell lines TE1, TE10, Kyse-30, Kyse-70, Kyse-150, ECA109 and normal esophageal epithelial cell line (HEEC) were bought from Fudan IBS Cell Center (Shanghai, China). All cells were cultured in RPMI 1640 (Gibco, Gaithersburg, USA) with 10% fetal bovine serum (FBS; Gibco) at 37°C, 95% humidity and 5% CO 2 .
Patients and specimens
Forty-seven paired tumor tissues and normal tissues were obtained from patients who were diagnosed as ESCC by means of pathology and were not subject to chemotherapy and/or radiotherapy at Sichuan Cancer Hospital (Chengdu, China) between January 2008 and December 2016. The age of patients ranged from 41 to 78, randomly selected by Department of Pathology. Other details of patients were shown in Table 1 . Diagnosis of ESCC was defined according to the tumor node metastasis stage and World Health Organization (WHO) criteria. The study was approved by the ethics committee of Sichuan Province Medical Association. The informed consent forms were signed by every patient. Tissues were stored in liquid nitrogen until use.
RNA extraction and quantitative real-time PCR
Total RNA was extracted from tissue specimens or the cultured cells using TRIzol ® reagent (TaKaRa, Dalian, China) following the manufacturer's protocol. The RNA concentration was measured with a spectrophotometer. The relative fluorescence was collected with SYBR Green dyestuff using STEP ONE RT-qPCR apparatus (Applied Biosystems, Foster, USA). For miRNA, the reverse transcription was conducted by two steps at 37°C for 5 min and 42°C for 25 min in 0.2 ml reaction system without RNA enzymes in accordance with the miRNA reverse transcription kit (Abm, Chengdu, China). For the real-time quantitative PCR (qRT-PCR) reaction, the reagents were added in 48-well PCR plates according to miRNA SYBR Green qRT-PCR kit (Abm) instruction. The annealing temperature was 65°C, 40 cycles.
For mRNA, the reverse transcription was conducted by two steps at 95°C for 5 min and 60°C for 15 min in 0.1 ml reaction system in accordance with the miRNA reverse transcription kit (Abm). qRT-PCR was performed at the annealing temperature of 60°C, 35 cycles. Relative gene expression levels were calculated by the ΔΔCt method. The primers used were listed in Table 2 .
Cell transfection
MiR-128-3p mimics (miR-128-3p), inhibitor (anti-miR-128-3p) and negative control were synthesized by Genechem Company (Shanghai, China). ZEB1 over-expression plasmid vector was purchased from the Genechem Company. All of these were confirmed by DNA sequence analysis. Cells were transfected using the reagent Lipofectamine 2000 (Invitrogen, Carlsbad, USA) in opti-RPMI 1640 (Gibco) according to manufacturer's instructions.
Luciferase reporter gene assay
The luciferase reporter gene plasmid pMIR was used to construct the ZEB1 3′UTR luciferase reporter gene plasmid. The miR-128-3p specific stem-loop primer was 5′-GTCGTATCCAGTGCAGGGTCC GAGGTATTCGCACTGGATACGACAAAGAG-3′. The wild-type miR-128 binding site at 3′UTR of ZEB1 was synthesized with the following primers: forward, 5′-AATATAAAACTTAAATTTTGAAA TTCACTGTGTGACTAATAGCATGATGCTCTGCAG-3′; reverse, 5′-TTAATAAAACTGCAGAGCATCATGCTATTAGTCACACAG TGAATTTCAAAATTTAAG-3′. The mutant binding site was synthesized with the following primers: forward, 5′-AATATAAAACTTAAA TTTTGAAATTTACGTTGTGACTAATAGCATGATGCTCTGCAG-3′; reverse, 5′-TTAATAAAACTGCAGAGCATCATGCTATTAGTCAC ACAGTGAATTTCAAAATTTAAG-3′. These wild-type or mutant 3′UTRs were subcloned into pMIR plasmid at the CMV/SacI site at the downstream of the luciferase vector, and defined as pZEB1-wt or pZEB1-mut, respectively.
Luciferase reporter gene assay was performed in 96-well plates using the Dual-Glo Luciferase Assay System (Promega, Madison, USA). Cells were co-transfected with miR-128-3p mimics and 10 μg of pZEB1-wt or pZEB1-mut by using Lipofectamine 2000 (Invitrogen, Carlsbad, USA). After 48 h, luciferase activity was measured using a Dual-Luciferase Reporter Assay kit (Promega) according to the manufacturer's instructions. SpectraMax M5 instrument software (Molecular devices, San Francisco, USA) was used to analyze the results. Each experiment was repeated three times. 
Western blot analysis
The total protein was extracted by ice-cold RIPA lysis buffer supplemented with phenylmethanesulfonyl fluoride (PMSF) and protease inhibitor cocktail. Cell lysates were mixed with loading buffer and subjected in 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by being transferred onto polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% skimmed milk for 2 h, followed by incubation with antibodies against E-cadherin, N-cadherin, Vimentin, β-catenin and ZEB1 (Abcam, Cambridge, UK) at 4°C overnight. Then the membranes were washed with TBST for three times and incubated with the corresponding horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology, Boston, USA) for another 1 h at 37°C. An enhanced ECL Chemiluminescence kit (UltraSignal, Beijing, China) was used to visualize the proteins according to the manufacturer's protocol. The signals were exposed to X-ray films. GAPDH was used as the loading control.
MTT assay
Cell proliferation was analyzed by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells were seeded at the density of 5 × 10 3 /well in 96-well plates, and cultured for 24-72 h. MTT solution (5 mg/ml; Sigma, St Louis, USA) was added into the medium and incubated for 4 h at 37°C. After removal of the medium, 100 μl of dimethyl sulfoxide (DMSO) was added into each well. The absorbance at 560 nm was measured with a microplate reader. All reactions were performed in triplicate.
Wound healing assay
Cells were seeded into 6-well plates with 5 × 10 5 cells/well and cultured in complete medium. When cell monolayer was formed, an artificial wound was scraped on the cells using a pipette tip. The ability of cells migrating from the confluent sides into the scratch area was observed. The width of the scratch gap was recorded under an inverted microscope and photographed at 6 h and 24 h. The difference between the original width of the wound and the width after cell migration was quantified. Three replicates of each condition were used.
Transwell invasion assay
For the transwell invasion assay, cells (5 × 10 3 /well) were directly added into the upper chambers of matrigel-coated Transwell plates (Corning Co, Corning, USA) with serum-free medium. The lower chamber contained culture medium with 4% FBS as a chemoattractant. After 24 h, cells on the top of the membrane were scraped off and migrated cells stuck under the membrane were stained with crystal violet. The invaded cells in five random fields were counted under a microscope. Each experiment was conducted for three times.
Immunofluorescence assay
Cells were cultured on cover slips for 24 h, followed by being fixed with cold acetone for 20 min. Then cells were incubated with antibodies against E-cadherin, N-cadherin, Vimentin and β-catenin at 4°C overnight, followed by incubation with the FITC-conjugated goat anti-rabbit secondary antibodies (Cell Signaling Technology, Boston, USA) for another 1 h. 4′,6-Diamidino-2-phenylindole (DAPI) was used to stain the nuclei of the cells. Finally, cells were observed under a fluorescence microscope. Each experiment was conducted for three times.
Statistical analysis
Data were presented as the mean ± SD. All statistical analyses were performed using SPSS 17.0 statistical software. Categorical variables were compared by using Fisher's exact test. Relationship between miR-128-3p expression and clinical features was analyzed by the Pearson χ 2 tests. Kaplan-Meier method was used to compare the overall survival curve between high miR-128-3p and low miR-128-3p expression groups by log-rank test. Cox proportional hazards regression model was made to identify hazard factors with overall survival in multivariate survival analysis for ESCC. In vitro assays and luciferase activities assay were analyzed by the Student's t-test. P < 0.05 was considered statistically significant.
Results
Down-regulated expression of miR-128-3p in ESCC tissues and ESCC cells
To identify the biological function of miR-128-3p, we first used qRT-PCR assay to detect the expression of miR-128-3p in ESCC tissues and cells to speculate and identify the biological function of miR-128-3p. The results of qRT-PCR assay demonstrated that the expression of miR-128-3p was lower in ESCC tissues and cells than that in normal esophageal epithelial tissues and cells (Fig. 1A-C) . These data indicated that miR-128-3p might function as a suppressor to hinder the tumorigenesis of ESCC.
Low expression of miR-128-3p is correlated with poor prognosis of patients in ESCC
To address the clinical significance of miR-128-3p in ESCC, 47 patients were employed to evaluate the correlations between miR-128-3p 
U6 and GAPDH were used as the internal references. All reactions were performed in triplicate.
expression level and the clinicopathological features. Kaplan-Meier method analysis (log-rank test) was used to confirm that miR-128-3p expression was associated with overall survival rates of patients (P = 0.002; Fig. 1D ). Correlation between miR-128-3p expression and clinical features analysis implied that miR-128-3p expression is correlated with tumor range and lymphatic metastasis (P = 0.036 and 0.018, respectively; Table 1 ). Proportional hazards method (Cox regression) analysis showed that low miR-128-3p expression (P = 0.042) was an adverse prognostic factor in addition to lymph nodes number (P = 0.013) and pathological stage (P = 0.001) ( Table 3) . Taken together, miR-128-3p has significant biological function and may be used as a specific biomarker for poor prognosis in ESCC.
MiR-128-3p suppresses invasion and metastasis in ESCC
To further define the potential biological significance of miR-128-3p in ESCC, we used miR-128-3p mimics and inhibitor to perform the gain and loss function analysis. MTT assay showed that up-regulation of miR-128-3p diminished ESCC cells proliferation, while downregulation of miR-128-3p enhanced ESCC cells proliferation ( Fig. 2A) . Meanwhile, the wound scratch healing assay revealed that the migratory ability of ESCC cells transfected with miR-128-3p was obviously lower than those transfected with miR-NC. The migratory ability of ESCC cells transfected with miR-128-3p inhibitor (anti-miR-128-3p)
Figure 1. Down-regulated expression of miR-128-3p in ESCC tissues and ESCC cells (A) qRT-PCR analysis detected the relative expression of miR-128-3p in ESCC tissues. (B) miR-128-3p expression in tissue samples of ESCC and adjacent normal tissues. (C) qRT-PCR analysis assessed the relative expression of miR-128-3p in ESCC cells. (D)
The overall survivals in 47 ESCC patients were represented by Kaplan-Meier curves. Each experiment was performed in triplicate. U6 was used as an internal control. *P < 0.05; **P < 0.01. A positive, independent prognostic importance of miR-128-3p expression (P = 0.042), in addition to the independent prognostic impact of lymph nodes number (P = 0.013) and pathological stage (P = 0.001). HR, hazard ratio. *P < 0.05 was considered statistically significant. was higher than those transfected with the negative control (antimiR-NC) (Fig. 2B) . Furthermore, the effects of miR-128-3p on invasion of ESCC cells were further investigated. Transwell assay showed that ectogenic miR-128-3p repressed the invasive ability of ESCC cells and knockdown of miR-128-3p increased the invasive ability of ESCC cells (Fig. 2C) . These results suggest that miR-128-3p Figure 2 . MiR-128-3p suppresses invasion and metastasis in ESCC (A) MTT assay was performed to detect cell proliferation ability. (B) Wound healing was photographed under a microscope at 100× magnification after 6 h and 24 h. (C) Transwell invasion assay was used to observe of invasion ability of ESCC cells after transfected with miR-NC, miR-128-3p, anti-miR-NC and anti-miR-128-3p. Cells were viewed in five random fields at 100× magnification and counted. Each experiment was performed in triplicate. **P < 0.01. may effectively suppress the growth, migration and invasion of ESCC cells in vitro.
EMT is regulated by miR-128-3p
To find out the underlying mechanism that miR-128-3p suppresses cell metastasis, qRT-PCR assay was conducted. It was found that miR-128-3p mimics could stimulate the expression of epithelial markers (E-cadherin and β-catenin), remarkably retard the expression of mesenchymal markers (Vimentin and N-cadherin) . Knockdown of miR-128-3p could repress the expression of epithelial markers (E-cadherin and β-catenin), and prominently induce the expression of mesenchymal markers (Vimentin and N-cadherin) (Fig. 3A) . Immunofluorescence assay showed that the expression of epithelial protein markers was increased in miR-128-3p-transfected ESCC cells, while the expression of mesenchymal protein markers was notably decreased. After transfection with anti-miR-128-3p, the expression of epithelial protein markers was significantly decreased in ESCC cells, while the expression of mesenchymal protein markers was strengthened (Fig. 3B) . These data suggest that miR-128-3p may suppress the EMT of ESCC cells in vitro.
ZEB1 is directly targeted by miR-128-3p in ESCC
It is well known that ZEB1 belongs to the ZEB family of transcription factors that can stimulate invasion and metastasis [32, 33] . This has also been confirmed in ESCC [34, 35] . However, the underlying Each experiment was performed in triplicate. GAPDH served as the internal control. **P < 0.01.
upstream factor was unknown. Therefore, luciferase reporter gene assay was performed to test whether ZEB1 was directly targeted by miR-128-3p in ESCC. It was found that miR-128-3p notably inhibited the luciferase activities when co-transfected with the wild-type ZEB1 3′UTR (Fig. 4A) , while the suppressive effects of miR-128-3p on luciferase activity were attenuated when the binding sequences were mutated in two ESCC cell lines (Fig. 4B) . Furthermore, qRT-PCR and western blot analysis results confirmed that ZEB1 is the direct target of miR-128-3p. qRT-PCR and western blot analysis results showed that the expression of ZEB1 was reduced by the over-expression of miR-128-3p, and the expression of ZEB1 was increased by knockdown of miR-128-3p (Fig. 4C-E) . These data imply that ZEB1 directly and negatively regulates miR-128-3p.
EMT is regulated by miR-128-3p via suppression of ZEB1 ZEB1 has been proved to induce cell EMT. However, the potential upstream target of ZEB1 to control EMT process in ESCC is still unknown. To explore whether the regulating effects of miR-128-3p on EMT are through suppressing ZEB1, rescue experiments were performed. It was found that the expression of epithelial markers (E-cadherin and β-catenin) and mesenchymal markers (Vimentin and N-cadherin) could be reversed by co-transfection with miR-128-3p mimics and ZEB1 (Fig. 5A,B) . These results indicate that miR-128-3p/ZEB1 axis plays an important role in modulating EMT process in ESCC. 
Discussion
ESCC is one of the most common cancers in China [32] . However, the prognosis of advanced ESCC patients remains poor [33] . EMT and MET have been viewed as regulatory mechanisms of invasion and metastasis in malignant tumors [34] [35] [36] [37] . Therefore, EMTrelated functions in malignancies have been considered as potential new therapeutic tool for cancers including ESCC.
ZEB1 has been previously reported as a strong functional gene which contributes to distant metastasis in colorectal adenocarcinoma, breast cancer and lung adenocarcinoma [38] [39] [40] . Moreover, ZEB1 has been found to be associated with cancer progression and EMT induction [41, 42] . Harazono et al. [43] found that EMT is inhibited by miR-655 via targeting ZEB1 and TGFBR2, which was regarded as potential prognostic markers and therapeutic agent for cancer. On the other hand, it has been reported that miR-150 is associated with poor prognosis in ESCC through targeting ZEB1 to induce EMT [44] . Over-expression of ZEB1 has been proved to induce ESCC invasiveness and generate unfavorable prognosis [45] . Zhang et al. [46] found that methylation of E-cadherin regulated by miR-200b-ZEB1/2 axis could promote invasion via activating the Kindlin-2/integrin β1/ AKT signal pathway in ESCC.
Recently, miRNAs have attracted much attention because of their biological roles in regulating gene expression in ESCC [47] [48] [49] . miRNAs are some tiny non-coding endogenous RNAs which take part in multiple tumorigenic processes of ESCC, including proliferation, invasion and metastasis [25, 48, 50] . Khan et al. [51] revealed that miR-128 regulates the progression of prostate cancer. In breast cancers, down-expression of miR-128 that releases Bmi-1 and overexpression of ABCC5 which is a feature of stem cell are involved in chemotherapeutic resistance [52] . It has also been found that miR-128 activates the PTEN-AKT pathway and miR-128 is downexpressed in pituitary tumors [53] . Similarly, miR-128-3p has been regarded as an inhibitor in the progression of HCC by regulating PIK3R1 and PI3K/AKT signal pathway, and has also been regarded as a prognostic marker for HCC patients [54] . In lung cancer, PFKL/miR-128 axis inhibits AKT signaling pathway, and leads to shorter survival time [55] . Jiang et al. [56] found that miR-128 could also reverse the gefitinib resistance of the lung cancer stem cells by blocking the c-met/PI3K/AKT pathway. In glioma, miR-128 was found to inhibit the growth of multiforme glioblastoma and stem-like cells by regulating BMI1 and E2F3 [57] .
But in another study, miR-128-3p was identified as an oncogene through targeting PHF6 in T-cell acute lymphoblastic leukemia [58] . MiR-128-3p is also upregulated in HCC, and it may be used as a potential biomarker for diagnosis in combination with CYP2C9 [59] . The expression level of miR-128-3p was found to be obviously higher in gastric cancer tissues compared with that in adjacent nontumor tissues, which was confirmed by PCR assay [60] .
In summary, although miR-128-3p has been reported to be lowexpressed in many cancers [61, 62] , its behavior in human ESCC remains unclear. In this study, we first tested the expression levels of miR-128-3p in ESCC tissues and ESCC cells, and found that miR-128-3p was markedly downregulated in ESCC tissues compared with that in adjacent normal esophageal tissues. Next, we found that low expression of miR-128-3p is correlated with poor prognosis of patients in ESCC, which indicated that MiR-128-3p might be a diagnostic indicator and prognostic factor. Then, we demonstrated that miR-128-3p is able to restrain proliferation, invasion, and metastasis in ESCC cells. Moreover, ZEB1 was confirmed to be the direct downstream target of miR-128-3p. Furthermore, miR-128-3p was found to target ZEB1 to block the EMT process. Taken together, our results indicate that miR-128-3p may reduce the proliferation, migration and metastasis of ESCC cells by targeting ZEB1 and inhibit the EMT process. miR-128-3p might be a sensitive prognostic factor and novel target therapy for ESCC treatment.
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